促肾上腺皮质激素释放因子在靶向抗癌治疗中的意义。
Implications of corticotropin releasing factor in targeted anticancer therapy.
作者信息
Kim Byung-Jin, Jones Harlan P
机构信息
Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
出版信息
J Pharm Pract. 2010 Apr;23(2):86-90. doi: 10.1177/0897190009360023. Epub 2010 Feb 17.
Abstract
There is a need to develop novel anticancer therapies that eliminate adverse side effects produced by current treatments. Corticotropin releasing factor (CRF), an endogenous neuroedocrine factor, which typically regulates biological and psychological indicators of stress, has recently been found to be expressed by tumor malignancies. Here, we discuss the implications of CRF as a target for antitumor therapy through regulation of tumor immune escape mechanisms.
摘要
有必要开发新型抗癌疗法，以消除当前治疗产生的不良副作用。促肾上腺皮质激素释放因子（CRF）是一种内源性神经内分泌因子，通常调节应激的生物学和心理指标，最近发现它在肿瘤恶性病变中表达。在此，我们通过调节肿瘤免疫逃逸机制来讨论CRF作为抗肿瘤治疗靶点的意义。
相似文献
1
Implications of corticotropin releasing factor in targeted anticancer therapy.
J Pharm Pract. 2010 Apr;23(2):86-90. doi: 10.1177/0897190009360023. Epub 2010 Feb 17.
2
Corticotropin-releasing factor receptor signaling and modulation: implications for stress response and resilience.
Trends Psychiatry Psychother. 2020 Jun;42(2):195-206. doi: 10.1590/2237-6089-2018-0027. Epub 2020 Jul 17.
3
Role of corticotropin-releasing factor family peptides and receptors in stress-related psychiatric disorders.
Semin Clin Neuropsychiatry. 2003 Apr;8(2):119-36. doi: 10.1053/scnp.2003.50011.
4
Role of corticotropin-releasing factor in drug addiction: potential for pharmacological intervention.
CNS Drugs. 2011 Apr;25(4):271-87. doi: 10.2165/11587790-000000000-00000.
5
The corticotropin-releasing factor family of peptides and CRF receptors: their roles in the regulation of energy balance.
Eur J Pharmacol. 2002 Apr 12;440(2-3):189-97. doi: 10.1016/s0014-2999(02)01428-0.
6
The roles of corticotropin-releasing factor-related peptides and their receptors in the cardiovascular system.
Curr Protein Pept Sci. 2006 Jun;7(3):229-39. doi: 10.2174/138920306777452358.
7
Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications.
J Physiol Pharmacol. 2009 Dec;60 Suppl 7(Suppl 7):33-46.
8
Region-specific roles of the corticotropin-releasing factor-urocortin system in stress.
Nat Rev Neurosci. 2016 Oct;17(10):636-51. doi: 10.1038/nrn.2016.94. Epub 2016 Sep 2.
9
Corticotropin-releasing factor receptors and urocortins, links between the brain and the heart.
Eur J Pharmacol. 2010 Apr 25;632(1-3):1-6. doi: 10.1016/j.ejphar.2010.01.027. Epub 2010 Feb 2.
10
Corticotropin releasing factor-binding protein (CRF-BP) as a potential new therapeutic target in Alzheimer's disease and stress disorders.
Transl Psychiatry. 2019 Oct 22;9(1):272. doi: 10.1038/s41398-019-0581-8.
引用本文的文献
1
Corticotropin-releasing factor reduces tumor volume, halts further growth, and enhances the effect of chemotherapy in 4T1 mammary carcinoma in mice.
Tumour Biol. 2014 Feb;35(2):1365-70. doi: 10.1007/s13277-013-1186-0. Epub 2013 Sep 18.
本文引用的文献
1
Corticotropin Releasing Factor promotes breast cancer cell motility and invasiveness.
Mol Cancer. 2009 Jun 2;8:30. doi: 10.1186/1476-4598-8-30.
2
Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic-pituitary-adrenal axis regulation.
Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9069-74. doi: 10.1073/pnas.0811949106. Epub 2009 May 18.
3
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.
Cancer Immun. 2009 Apr 2;9:3.
4
Angiogenesis in adrenocortical physiology and tumor development.
Ann Endocrinol (Paris). 2009 Jun;70(3):153-5. doi: 10.1016/j.ando.2009.02.005. Epub 2009 Mar 14.
5
A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention.
Cancer Res. 2009 Feb 15;69(4):1243-54. doi: 10.1158/0008-5472.CAN-09-0029. Epub 2009 Feb 10.
6
A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma.
Hum Immunol. 2009 Jan;70(1):60-4. doi: 10.1016/j.humimm.2008.10.020. Epub 2008 Nov 21.
7
Is norepinephrine an etiological factor in some types of cancer?
Int J Cancer. 2009 Jan 15;124(2):257-63. doi: 10.1002/ijc.24063.
8
Tumor-stroma interactions influence cytokine expression and matrix metalloproteinase activities in paired primary and metastatic head and neck cancer cells.
Cell Biol Int. 2009 Feb;33(2):165-73. doi: 10.1016/j.cellbi.2008.10.009. Epub 2008 Nov 1.
9
Ursolic acid inhibits IL-1beta or TNF-alpha-induced C6 glioma invasion through suppressing the association ZIP/p62 with PKC-zeta and downregulating the MMP-9 expression.
Mol Carcinog. 2009 Jun;48(6):517-31. doi: 10.1002/mc.20490.
10
Tumor dormancy and immunoescape.
APMIS. 2008 Jul-Aug;116(7-8):685-94. doi: 10.1111/j.1600-0463.2008.01163.x.
Zotero 插件